CASI - CASI Pharma's CD19 CAR-T nabs accelerated review in China for a type of blood cancer

The Chinese Center for Drug Evaluation has granted Breakthrough Therapy Designation to CASI Pharmaceuticals' (CASI) partner Juventas Cell Therapy, for CNCT19, a CD19 CAR-T therapy for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukemia.CASI has co-commercial rights to CNCT19 and is a shareholder of Juventas.CNCT19 targets CD19, a B-cell surface protein widely expressed during all phases of B-cell development and a validated target for B-cell driven hematological malignancies.Last month Juventas completed $65M financing and enrolled the first patient in a Phase 2 study for CNCT19 in China in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

For further details see:

CASI Pharma's CD19 CAR-T nabs accelerated review in China for a type of blood cancer